Biotech News

Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London

Supernus (SUPN)SupernusConference / presentation

ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus, Inc., will

Related news

Supernus

CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...

Recent company news

Stock data

Close
28.35 USD
Market cap
2.56B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States